Table 3.

Clinically accepted nanoformulations for cancer treatment.

S.No	Trade name along with company	Type of nanocarrier with particle size/Targeting mechanism	Indication	Year approved	Route of administration	References
1	Doxil (Janssen)	Liposomal doxorubicin (PEGylated), 80–90 nm, passive targeting	Ovarian carcinoma, AIDS-related Kaposi’s sarcoma	FDA in 1995 EMA in 1996	Intravenous injection	(Anselmo & Mitragotri, 2019)
2	Zinostatin stimalamer (Pharma of Yamanouchi and Astellas)	Copolymer conjugated formulation of Zinostatin with polystyrene-co-maleic acid-half-butylate, passive targeting	Hepatocellular carcinoma (HCC)	Japan in 1994	Intra-arterial injection	(T.W. Liu et al., 2013)
3	Genexol (Samyang Biopharm)	Paclitaxel loaded polymeric micelle, 20–50 nm, passive targeting	Breast cancer that is metastatic and recurrent	South Korea in 2006	Intravenous injection	(Weissig et al., 2014)
4	Eligard (Tolmar)	Polymeric matrix product of leuprolide acetate, passive targeting	Prostate cancer	FDA in 2002	Subcutaneous injection	(Werner et al., 2013)
5	DepoCyt (SkyPharma Inc.)	Liposomal cytarabine, 10–20 µm, passive targeting	Lymphomatous meningitis	FDA in 2007	Intrathecal injection	(Thakor & Gambhir, 2013)
6	Oncaspar (Enzon Pharma)	Covalent coloaded formulation of PEG with L-asparaginase, 50–200 nm, passive targeting	Acute lymphocytic leukemia	FDA in 1994	Intravenous or intramuscular injection	(Dinndorf et al., 2007)
7	Kadcyla (Roche)	Conjugation of herceptin to microtubule assembly inhibitor, active targeting	Early-stage HER2-positive breast tumor	FDA in 2019	Intravenous injection	(Alphandery et al., 2015)
8	NanoTherm (MagForce)	Superparamagnetic iron coated with aminosilane (hyperthermia, treatment), 20 nm, magnetic targeting	Glioblastoma	EMA in 2013	Intratumoral injection	(Martinelli et al., 2019)